Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lorbrena Filed as 1st Line Therapy for ALK-Positive Lung Cancer: Pfizer
December 16, 2020
- PIII Trial Launched for DS-1062 in NSCLC: Daiichi Sankyo/AZ
December 16, 2020
- Efient Filed for Label Expansion to Prevent Ischemic Stroke Recurrences
December 16, 2020
- Ono Licenses MALT1 Inhibitor for Blood Cancer Treatments from Takeda Spin-Off Chordia
December 16, 2020
- Filing for SanBio’s Sakigake Cell Therapy for TBI Likely to Be Delayed
December 16, 2020
- Solasia’s Peripheral Neuropathy Drug Fails in PIII in Colorectal Cancer Patients
December 16, 2020
- Pfizer, Life Data Initiative, NTT Data Tie Up on Big Data Research on Cancer Outcome Evaluation
December 15, 2020
- Enhertu Gets CHMP Backing for HER2-Positive Breast Cancer
December 15, 2020
- Kobayashi Kako Temporary Halts Shipments of All Products after Tainted Itraconazole Issue
December 15, 2020
- Forxiga Filed for Chronic Kidney Disease in Japan: AZ
December 15, 2020
- Authorized Generics for Lyrica, ComPlavin, Memary Dry Syrup Now Available
December 14, 2020
- Astellas Sees More R&D Collaborations in Gene Therapy, I/O as It Looks beyond Xtandi LOE
December 14, 2020
- 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
December 14, 2020
- Takeda Launches Buccal Midazolam for Status Epilepticus
December 14, 2020
- AstraZeneca, Japan Govt Ink Definitive Deal on COVID-19 Vaccine
December 11, 2020
- Chugai to Develop Regeneron’s COVID-19 Antibody Cocktail in Japan
December 11, 2020
- Boehringer Speeding Up Growth of Jardiance on Organization, Alliance Rejig; 40 Billion Yen Japan Sales Likely in 2020
December 11, 2020
- Ono Newly Files Opdivo as First-Line Treatment for Gastric Cancer with Additional Data
December 11, 2020
- Aducanumab Submitted in Japan, but Decision Unlikely to Come Until Next Autumn
December 11, 2020
- Nichi-Iko Recalls 4 More Products Including Theophylline due to Deviations from Approved Specifications
December 11, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…